Literature DB >> 7790080

Mucosal immunogenicity of polysaccharides conjugated to a peptide or multiple-antigen peptide containing T- and B-cell epitopes.

E Lett1, C Klopfenstein, J P Klein, M Schöller, D Wachsmann.   

Abstract

In this study we investigated the mucosal and systemic responses to two T-cell-independent polysaccharides, a serogroup f polysaccharide (formed of rhamnose glucose polymers [RGPs]) from Streptococcus mutans OMZ 175 and a mannan from Saccharomyces cerevisiae, covalently conjugated either to a linear peptide (peptide 3) or to a multiple-antigen peptide (MAP), both derived from S. mutans protein SR, an adhesin of the I/II protein antigen family of oral streptococci. Peptide 3 and MAP, which contained at least one B- and one T-cell epitope, were tested as carriers for the polysaccharides and as protective immunogens. Intragastric intubation of rats with the conjugates (RGPs-peptide 3, RGPs-MAP, mannan-peptide 3, and mannan-MAP) associated with liposomes produced salivary immunoglobulin A (IgA) antibodies which reacted with RGPs or mannan, peptide 3 or MAP, protein SR, and S. mutans or S. cerevisiae cells. Administration of conjugate boosters to the animals showed that both carriers conjugated to the polysaccharides were able to induce, in immunized animals, a salivary antipolysaccharide IgA memory. In contrast, animals primed and challenged with unconjugated polysaccharide showed no anamnestic response. Rats orally immunized with the conjugates also developed systemic primary antipolysaccharide and antipeptide IgM antibody responses which were characterized by a switch from IgM to IgG during the course of the secondary response. Data presented here demonstrated that both peptide 3 and the MAP construct can act as good carriers for orally administered polysaccharides. Unexpectedly, the use of a MAP did not further improve the immunogenicity of polysaccharides at the mucosal level; nevertheless, such a construct should be of great interest in overcoming the problem of genetic restriction induced by linear peptides.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7790080      PMCID: PMC173354          DOI: 10.1128/iai.63.7.2645-2651.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Application and limitations of the multiple antigen peptide (MAP) system in the production and evaluation of anti-peptide and anti-protein antibodies.

Authors:  J P Briand; C Barin; M H Van Regenmortel; S Muller
Journal:  J Immunol Methods       Date:  1992-12-08       Impact factor: 2.303

2.  Immunogenicity of multiple antigen peptides (MAP) containing T and B cell epitopes of the repeat region of the P. falciparum circumsporozoite protein.

Authors:  D Y Munesinghe; P Clavijo; M C Calle; R S Nussenzweig; E Nardin
Journal:  Eur J Immunol       Date:  1991-12       Impact factor: 5.532

3.  Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.

Authors:  E L Anderson; T Bowers; C M Mink; D J Kennedy; R B Belshe; H Harakeh; L Pais; P Holder; G M Carlone
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

4.  Immunogenicity of polysaccharides conjugated to peptides containing T- and B-cell epitopes.

Authors:  E Lett; S Gangloff; M Zimmermann; D Wachsmann; J P Klein
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

5.  Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines.

Authors:  C C Peeters; A M Tenbergen-Meekes; J T Poolman; M Beurret; B J Zegers; G T Rijkers
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

6.  Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era.

Authors:  W G Adams; K A Deaver; S L Cochi; B D Plikaytis; E R Zell; C V Broome; J D Wenger
Journal:  JAMA       Date:  1993-01-13       Impact factor: 56.272

7.  Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine.

Authors:  T Barington; A Gyhrs; K Kristensen; C Heilmann
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

8.  Immunogenicity of multiple antigen peptides containing B and non-repeat T cell epitopes of the circumsporozoite protein of Plasmodium falciparum.

Authors:  J M Calvo-Calle; G A de Oliveira; P Clavijo; M Maracic; J P Tam; Y A Lu; E H Nardin; R S Nussenzweig; A H Cochrane
Journal:  J Immunol       Date:  1993-02-15       Impact factor: 5.422

9.  Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components.

Authors:  T Barington; M Skettrup; L Juul; C Heilmann
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

10.  Antigenicity and immunogenicity of a synthetic peptide derived from a glucan-binding domain of mutans streptococcal glucosyltransferase.

Authors:  D J Smith; M A Taubman; C F Holmberg; J Eastcott; W F King; P Ali-Salaam
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

View more
  1 in total

1.  Persistence of serum and salivary antibody responses after oral immunization with a bacterial protein antigen genetically linked to the A2/B subunits of cholera toxin.

Authors:  G Hajishengallis; S M Michalek; M W Russell
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.